Change over period: —
NSE · BAJAJHCARE
BAJAJHCARE
-28.7% from the 52-week high · +16.5% above the low
Bajaj Healthcare Ltd. is a pharmaceutical company, which is engages in the development, manufacturing, and supply of amino acids, nutritional supplements, and active pharmaceutical ingredients. The company is headquartered in Thane, Maharashtra and currently employs 1,063 full-time employees. The company went IPO on 2016-05-10. The firm is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. The company is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. The company also offers Inositol Nicotinate and Magnesium L-Threonate.
The short version. Promoter holding was 58.59% in Sep 2026, down 0.60 points over 8 quarters.
1 · The price
How has the stock traded?
BAJAJHCARE trades 28.7% below its 52-week high and 16.5% above its 52-week low.
4 · The owners
Who holds it, and are they adding?
Down 0.6 pts over 8 quarters.
Up 1.08 pts over 8 quarters.
Down 0.4 pts over 8 quarters.
+1 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.19 | 59.19 | 59.19 | 59.19 | 59.19 | 58.29 | 58.59 | 58.59 | -0.6 |
| FII | 1.01 | 1.05 | 1.09 | 1.12 | 1.18 | 1.98 | 2.19 | 2.09 | +1.08 |
| DII | 2.36 | 2.52 | 3.16 | 3.0 | 2.96 | 2.91 | 1.92 | 1.96 | -0.4 |
| Public | 37.45 | 37.24 | 36.56 | 36.7 | 36.67 | 36.82 | 37.3 | 37.36 | -0.09 |
Mutual fund holdings · Oct 2026
3 schemes hold this stock
2 the month before.
- HDFC Pharma and Healthcare Fund0.48% of NAV
- Motilal Oswal BSE Healthcare ETF0.02% of NAV
- Bandhan BSE Healthcare Index Fund0.02% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for BAJAJHCARE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about BAJAJHCARE
What is the BAJAJHCARE share price?
BAJAJHCARE (BAJAJHCARE) last closed at ₹318.70, down 0.48% on the day. Its 52-week range is ₹274.95 to ₹449.20.
What is the market cap of BAJAJHCARE?
BAJAJHCARE has a market capitalisation of about ₹1,078 crore. Its price-to-earnings ratio is 43.4.
How are BAJAJHCARE's latest results?
Promoter holding was 58.59% in Sep 2026, down 0.60 points over 8 quarters.
Who owns BAJAJHCARE?
As of Sep 2026, shareholding was: Promoter 58.59%, FII 2.09%, DII 1.96%, Public 37.36%.
How many mutual funds hold BAJAJHCARE?
3 mutual fund schemes held BAJAJHCARE in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 19 Sep 2025 · Final Dividend - Rs. 1
- 23 Sep 2024 · Final Dividend - Rs. 1
- 22 Sep 2023 · Final Dividend - Rs. 1
- 22 Sep 2022 · Final Dividend - Rs. 1.5
- 28 Sep 2021 · Stock Split From Rs.10/- to Rs.5/-
- 28 Sep 2021 · Special Dividend - Rs. 0.5
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.